ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0906

Podocyte-Specific Induction of KLF6 Attenuates Diabetic Kidney Disease in Mice

Session Information

Category: Diabetic Kidney Disease

  • 601 Diabetic Kidney Disease: Basic

Authors

  • Owusu Frimpong, Bismark, Division of Nephrology, Department of Medicine, Stony Brook University, Stony Brook, New York, United States
  • Gujarati, Nehaben A., Division of Nephrology, Department of Medicine, Stony Brook University, Stony Brook, New York, United States
  • Mallipattu, Sandeep K., Division of Nephrology, Department of Medicine, Stony Brook University, Stony Brook, New York, United States
Background

Krüppel-Like Factor 6 (KLF6), a zinc finger transcription factor, is a key regulator of cytochrome c oxidase assembly in the podocytes. Podocyte-specific Klf6 knockdown increases the susceptibility to streptozotocin (STZ) induced-diabetic kidney disease (DKD). However, salutary effects of podocyte-specific KLF6 induction in DKD remain to be explored.

Methods

Podocyte-specific inducible human KLF6 (hKLF6) was generated in mice using the “Tet-on” system, by breeding NPHS2-rtTA mice with newly generated TRE-hKLF6 to generate hKLF6PODTA mice. TRE-KLF6 transgene were generated using the (TetO)7/CMV regulatory element driving the full-length human KLF6 coding sequence (CCDS 7060.1). Transgene was purified from plasmid vector sequences and microinjected into the pronucleus of FVB/N single-celled embryos. Founder mice were selected based on the level of hKLF6 induction after doxycycline (DOX) treatment. STZ + Unilateral nephrectomy (STZ-UNX) was utilized to induce DKD in mice. First, DOX diet was administered at 8 weeks of age in all mice. UNX or Sham was performed at 10 weeks of age followed by low-dose STZ or vehicle (VEH) treatment respectively, at 12 weeks for 5 consecutive days. DOX-STZ-UNX treated NPHS2-rtTA, DOX-VEH-Sham treated NPHS2-rtTA and hKLF6PODTA mice served as controls. All mice were euthanized at 20 weeks of age and assessed for functional and histological changes in the kidney.

Results

DOX-STZ-UNX treated hKLF6PODTA mice exhibited significantly lower albuminuria, focal and global glomerulosclerosis, mesangial expansion, and improved mice survival as compared to age and gender-matched DOX-STZ-UNX treated NPHS2-rtTA mice. DOX-STZ-UNX treated hKLF6PODTA mice also exhibited less tubulointerstitial fibrosis and inflammation (pathology scoring) as compared to age- and gender-matched DOX-STZ-UNX treated NPHS2-rtTA mice.

Conclusion

These data suggest that podocyte-specific induction of human KLF6 attenuates podocyte injury and DKD, and improves overall survival in mice.

Funding

  • NIDDK Support